Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma-Reference-Cited by-同舟云学术

Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma

Published:2018-12-07 Issue:23 Volume:2 Page:3479-3482
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Wang Chia-Ching¹,Thanh Cassandra¹,Gibson Erica A.¹,Ball-Burack Maya¹,Hogan Louise E.¹,Descours Benjamin²,Jones Norman¹,Carvidi Alexander B.¹,Munter Sadie¹,Bakkour Sonia³,Busch Michael P.³,Milush Jeffrey M.¹,Deeks Steven G.¹,Henrich Timothy J.¹

Affiliation:

1. Department of Medicine, University of California San Francisco, San Francisco, CA;

2. Molecular Virology Unit, Human Genetic Institute, Centre National de la Recherche Scientifique, Montpellier, France; and

3. Blood Systems Research Institute, San Francisco, CA

Abstract

Key Points Anti-CD30 therapy for Hodgkin lymphoma led to transient loss of detectable CD4+ T-cell HIV RNA and a decrease in residual plasma viremia. Targeting nonviral markers expressed on HIV-1 transcriptionally active cells may lead to reduced measures of HIV-1 persistence.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/23/3479/1630016/advances024364.pdf

Reference16 articles.

1. International AIDS Society global scientific strategy: towards an HIV cure 2016;Deeks;Nat Med,2016

2. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30;Hogan;PLoS Pathog,2018

3. Markers of the HIV-1 reservoir: facts and controversies;Bruel;Curr Opin HIV AIDS,2018

4. High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS;Pizzolo;AIDS,1994

5. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome;Rizzardi;AIDS,1996

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimising treatment of HIV-associated Hodgkin lymphoma;The Lancet Haematology;2023-08

2. Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article;International Immunopharmacology;2022-04

3. RNA delivery for cancer gene therapy;RNA Therapeutics;2022

4. Consenso mexicano de linfoma de Hodgkin;Gaceta de M�xico;2021-07-29

5. Immunodeficiency-associated Hodgkin lymphoma;Expert Review of Hematology;2021-06-03